Nebenwirkungen bei der Anwendung von Blutprodukten

1) *Bayston KF, Cohen J. Bacterial endotoxin and current concepts in the diagnosis and treatment of endotoxaemia. J Med Microbiol 1990;**31**: 73-83.*

2) *Schrezenmeier H, Walther-Wenke G, Muller TH, et al. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007;**47**: 644-52.*

3) *Walther-Wenke G, Schrezenmeier H, Deitenbeck R, et al. Screening of platelet concentrates for bacterial contamination: spectrum of bacteria detected, proportionof transfused units, and clinical follow-up. Ann Hematol 2009.*

4) *de Korte D, Curvers J, de Kort WL, et al. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006;**46**: 476-85.*

5) *Pietersz RN, Engelfriet CP, Reesink HW, et al. Detection of bacterial contamination of platelet concentrates. Vox Sang 2007;**93**: 260-77.*

6) *te Boekhorst PA, Beckers EA, Vos MC, et al. Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 2005;**45**: 514-9.*

7) *Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007;**47**: 1134-42.*

8) *Fang CT, Chambers LA, Kennedy J, et al. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion 2005;**45**: 1845-52.*

9) *Jansen GA, van Vliet HH, Vermeij H, et al. Functional characteristics of photochemically treated platelets. Transfusion 2004;**44**: 313-9.*

10) *Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006;**35**: 5-17.*

11) *Mohr H, Steil L, Gravemann U, et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009.*

12) *Stormer M, Vollmer T, Kleesiek K, Dreier J. Spore-forming organisms in platelet concentrates: a challenge in transfusion bacterial safety. Transfus Med 2008;**18**: 371-6.*

13) *Schmidt M, Karakassopoulos A, Burkhart J, et al. Comparison of three bacterial detection methods under routine conditions. Vox Sang 2007;**92**: 15-21.*

14) *McDonald CP, Pearce S, Wilkins K, et al. Pall eBDS: an enhanced bacterial detection system for screening platelet concentrates. Transfus Med 2005;**15**: 259-68.*

15) *Holme S, McAlister MB, Ortolano GA, et al. Enhancement of a culture-based bacterial detection system (eBDS) for platelet products based on measurement of oxygen consumption. Transfusion 2005;**45**: 984-93.*

16) *Mohammadi T, Pietersz RN, Vandenbroucke-Grauls CM, et al. Detection of bacteria in platelet concentrates: comparison of broad-range real-time 16S rDNA polymerase chain reaction and automated culturing. Transfusion 2005;**45**: 731-6.*

17) *Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 2002;**148**: 257-66.*

18) *Stormer M, Kleesiek K, Dreier J. High-volume extraction of nucleic acids by magnetic bead technology for ultrasensitive detection of bacteria in blood components. Clin Chem 2007;**53**: 104-10.*

19) *Schmidt M, Hourfar MK, Nicol SB, et al. A comparison of three rapid bacterial detection methods under simulated real-life conditions. Transfusion 2006;**46**: 1367-73.*

20) *Schmidt M, Hourfar MK, Nicol SB, et al. FACS technology used in a new rapid bacterial detection method. Transfus Med 2006;**16**: 355-61.*

21) *Mohr H, Lambrecht B, Bayer A, et al. Sterility testing of platelet concentrates prepared from deliberately infected blood donations. Transfusion 2006;**46**: 486-91.*

22) *Dreier J, Vollmer T, Kleesiek K. Novel flow cytometry-based screening for bacterial contamination of donor platelet preparations compared with other rapid screening methods. Clin Chem 2009;**55**: 1492-502.*

23) *SHOT report 2006; http://www.shotuk.org/home.htm.*

24) *Keller-Stanislawski B, Lohmann A, Gunay S, et al. The German Haemovigilance System--reports of serious adverse transfusion reactions between 1997 and 2007. Transfus Med 2009;**19**: 340-9.*

25) *Keller-Stanislawski B, Reil A, Gunay S, Funk MB. Frequency and severity of transfusion-related acute lung injury-German haemovigilance data (2006-2007). Vox Sang;**98**: 70-7.*

26) *Silliman CC, Curtis BR, Kopko PM, et al. Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model. Blood 2007;**109**: 1752-5.*

27) *Sachs UJ, Hattar K, Weissmann N, et al. Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. Blood 2006;**107**: 1217-9.*

28) *Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis 1983;**128**: 185-9.*

29) *Bux J. Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sang 2005;**89**: 1-10.*

30) *Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005;**33**: 721-6.*

31) *Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007;**136**: 788-99.*

32) *Nguyen, Dostmann, 2009.*

33) *Kao KJ, Scornik JC, Riley WJ, McQueen CF. Association between HLA phenotype and HLA concentration in plasma or platelets. Hum Immunol 1988;**21**: 115-24.*

34) *Reil A, Keller-Stanislawski B, Gunay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008;**95**: 313-7.*

35) *Win N, Chapman CE, Bowles KM, et al. How much residual plasma may cause TRALI? Transfus Med 2008;**18**: 276-80.*

36) *Odent-Malaure H, Quainon F, Ruyer-Dumontier P, et al. Transfusion related acute lung injury (TRALI) caused by red blood cell transfusion involving residual plasma anti-HLA antibodies: a report on two cases and general considerations. Clin Dev Immunol 2005;**12**: 243-8.*

37) *Nguyen XD, Flesch B, Sachs UJ, et al. Rapid screening of granulocyte antibodies with a novel assay: flow cytometric granulocyte immunofluorescence test. Transfusion 2009.*

38) *Gedye R. German AIDS scandal infects Europe. BMJ 1993;**307**: 1229.*

39) *Hourfar MK, Jork C, Schottstedt V, et al. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008;**48**: 1558-66.*

40) *Blumberg BS, Hesser JE, Economidou I, et al. The variety of responses within a community to infection with Australia (hepatitis B) antigen. Dev Biol Stand 1975;**30**: 270-83.*

41) *Candotti D, Grabarczyk P, Ghiazza P, et al. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 2008;**49**: 537-47.*

42) *Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;**43**: 788-98.*

43) *Assal A, Barlet V, Deschaseaux M, et al. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Transfusion 2009;**49**: 301-10.*

44) *Kubanek B, Cardoso M, Gluck D, Koerner K. [Risk of infection transmission by blood components]. Infusionsther Transfusionsmed 1993;**20**: 54-9.*

45) *Kretzschmar E, Chudy M, Nubling CM, et al. First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays. Vox Sang 2007;**92**: 297-301.*

46) *Schmidt M, Korn K, Nubling CM, et al. First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009;**49**: 1836-44.*

47) *Schmidt M, Themann A, Drexler C, et al. Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion 2007;**47**: 1775-82.*

48) *Kleinman SH, Glynn SA, Lee TH, et al. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009;**114**: 3677-83.*

49) *Schmidt M, Pichl L, Jork C, et al. Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes. Vox Sang;**98**: 37-46.*

50) *Wiedmann M, Kluwick S, Walter M, et al. HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas TaqScreen MPX test in seroconverting donors. J Clin Virol 2007;**39**: 282-7.*

51) *Yang MH, Li L, Hung YS, et al. The efficacy of individual-donation and minipool testing to detect low-level hepatitis B virus DNA in Taiwan. Transfusion 2009.*

52) *Vermeulen M, Lelie N, Sykes W, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009;**49**: 1115-25.*